Gilead Sciences, Inc. and Merck & Co., Inc. announced positive topline results from two Phase 3 studies evaluating islatravir and lenacapavir as an investigational oral once-weekly HIV treatment for virologically suppressed adults. Separately, Merck & Co., Inc. and Gilead Sciences, Inc. disclosed that the Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer will be discontinued after the combination failed to show a statistically significant progression-free survival benefit and was unlikely to meet the planned overall survival goal.
Why does the islatravir and lenacapavir Phase 3 result matter for long-acting HIV treatment?
The stronger signal in the dual update is the HIV readout, because the Phase 3 ISLEND-1 and ISLEND-2 studies move the islatravir and lenacapavir combination closer to a new treatment category rather than a routine label expansion. If approved, the regimen could become the first long-acting oral HIV treatment taken once weekly, placing it between daily oral antiretroviral therapy and longer-interval injectable options. That positioning matters because HIV treatment has already achieved high virologic control for many patients, which means innovation increasingly depends on reducing treatment burden without compromising suppression.
The clinical bar in switch studies is different from the bar in trials for treatment-naive or heavily treatment-experienced patients. ISLEND-1 compared once-weekly islatravir and lenacapavir with Biktarvy in virologically suppressed people, while ISLEND-2 compared the same investigational regimen with ongoing standard daily oral antiretroviral therapy. The primary endpoint in both trials focused on the proportion of participants with HIV-1 RNA of at least 50 copies per millilitre at Week 48, using the U.S. Food and Drug Administration snapshot algorithm. The non-inferiority outcome is therefore clinically meaningful because it suggests that reduced dosing frequency did not come at the cost of virologic control in the studied switch population.
The unresolved question is whether detailed data will support broad confidence beyond the topline claim. Regulators, clinicians and payers will want to see discontinuation rates, resistance outcomes, CD4 cell count trends, adherence patterns, and subgroup performance. A once-weekly oral HIV medicine may sound simple, but missed weekly doses could have different pharmacologic consequences from missed daily doses, particularly when two long-acting agents are paired. The regimen’s commercial potential will depend not only on efficacy, but also on whether clinicians believe it is forgiving enough for real-world use.
What does the result reveal about Gilead Sciences, Inc.’s next HIV franchise strategy?
For Gilead Sciences, Inc., the result strengthens the idea that lenacapavir is becoming a platform molecule rather than a single-product asset. Lenacapavir’s capsid inhibition mechanism gives Gilead Sciences, Inc. a differentiated scientific base across HIV treatment and prevention, while the once-weekly oral approach creates a potential bridge between Biktarvy-style daily therapy and long-acting injectable models. That is strategically important because Gilead Sciences, Inc. still relies heavily on HIV revenue, with Biktarvy remaining one of its largest commercial products.
The commercial context is straightforward but demanding. Biktarvy generated $14.3 billion in full-year 2025 sales, making any future switch strategy both attractive and delicate. A once-weekly oral regimen could defend Gilead Sciences, Inc.’s dominant HIV position by giving clinicians another reason to keep patients within the franchise. However, it could also raise sequencing questions if payers see the therapy as a premium convenience product rather than a medically necessary advance for most virologically suppressed patients.
The risk is that convenience alone rarely guarantees rapid uptake in chronic therapy markets unless it is matched by clean safety, clear adherence advantages, and manageable pricing. HIV treatment is a highly competitive and clinically conservative space because existing daily regimens already perform very well for many patients. Industry observers are likely to watch whether Gilead Sciences, Inc. can present once-weekly treatment as more than lifestyle convenience, especially for patients dealing with pill fatigue, stigma, privacy concerns, or complex daily routines.
Why is Merck & Co., Inc.’s islatravir comeback clinically important but still carefully watched?
For Merck & Co., Inc., the islatravir result is especially important because the molecule had previously carried a safety overhang related to lymphocyte and CD4 cell count decreases observed in earlier development. The Phase 3 statement that the safety profile was generally comparable with comparator regimens and that no new safety concerns were identified is therefore a meaningful development. It suggests that the lower-dose strategy and combination approach may have helped reopen a path for islatravir in HIV treatment.
The clinical significance lies in the mechanism. Islatravir is a nucleoside reverse transcriptase translocation inhibitor, while lenacapavir inhibits the HIV capsid and disrupts multiple stages of the viral lifecycle. Combining two distinct long-acting mechanisms could give the regimen a differentiated profile, especially if detailed data show durable suppression, a low resistance signal, and acceptable immunologic trends. In a field where incremental formulation changes can be mistaken for innovation, this pairing has a stronger scientific rationale than simple dosing convenience.
The limitation is that regulators may apply closer scrutiny precisely because of islatravir’s development history. A positive Week 48 non-inferiority result is important, but it is not the whole regulatory story. Longer follow-up through Week 96, immune cell monitoring, adverse event discontinuations, and performance in diverse populations will matter. The commercial question is whether Merck & Co., Inc. can convert a revived HIV candidate into a durable franchise contributor at a time when its broader investor narrative remains heavily tied to oncology diversification and Keytruda lifecycle management.
How does the KEYNOTE-D46/EVOKE-03 discontinuation change expectations for Trodelvy in lung cancer?
The oncology update cuts in the opposite direction. KEYNOTE-D46/EVOKE-03 tested Trodelvy, also known as sacituzumab govitecan-hziy, in combination with Keytruda, also known as pembrolizumab, against Keytruda alone in previously untreated metastatic non-small cell lung cancer with PD-L1 tumour proportion score of at least 50 percent and without sensitising EGFR, ALK or ROS1 alterations. The study enrolled around 620 patients globally, which makes the discontinuation a meaningful signal rather than a small exploratory setback.
The study design targeted a commercially important but difficult setting. Keytruda monotherapy is already a deeply entrenched first-line standard for high PD-L1 metastatic non-small cell lung cancer, so adding an antibody-drug conjugate needed to show a clear enough benefit to justify additional toxicity, infusion complexity, and cost. A numerical improvement in progression-free survival that did not reach statistical significance is not enough in this setting, particularly when the probability of a statistically significant overall survival result was considered unlikely.
The risk for Gilead Sciences, Inc. is not that Trodelvy loses its approved breast cancer role, but that its broader solid tumour expansion thesis becomes more selective. Trodelvy has commercial traction, with first-quarter 2026 sales rising 37 percent to $402 million, but lung cancer would have represented a larger opportunity than its established breast cancer indications. The failed first-line metastatic non-small cell lung cancer combination adds pressure on Gilead Sciences, Inc. to prove that Trodelvy’s value can extend beyond the tumour types where it already has stronger evidence.
What does the lung cancer readout say about the limits of immunotherapy and antibody-drug conjugate combinations?
The KEYNOTE-D46/EVOKE-03 outcome is also a reminder that combining a checkpoint inhibitor with an antibody-drug conjugate does not automatically create a better oncology regimen. The biological hypothesis is attractive because antibody-drug conjugates may increase tumour cell killing and antigen release, while immune checkpoint blockade may help sustain anti-tumour activity. However, lung cancer has repeatedly shown that plausible synergy still needs to survive the harder tests of endpoint hierarchy, tolerability, patient selection, and survival.
The control arm mattered. Keytruda monotherapy is not a weak comparator in high PD-L1 metastatic non-small cell lung cancer. It is a standard that already delivers durable benefit in a subset of patients, which means any add-on therapy must generate a clinically convincing improvement without eroding the risk-benefit balance. Trodelvy’s known safety profile includes toxicities such as neutropenia, diarrhoea, nausea, vomiting, and fatigue, so clinicians would need a strong efficacy reason to add it upfront.
The limitation is that the topline update does not yet show the full dataset. It remains unclear whether any biomarker-defined subgroup benefited, whether early progression patterns differed, or whether safety and treatment discontinuation affected exposure. However, the discontinuation decision indicates that the combination is unlikely to support a broad first-line development path in the tested population. For industry observers, the readout reinforces a familiar lesson: antibody-drug conjugate combinations need tighter patient selection, not merely larger trials.
Why does this split update create different investor messages for Gilead Sciences, Inc. and Merck & Co., Inc.?
For Gilead Sciences, Inc., the market signal is mixed but not evenly balanced. The HIV news supports the company’s strongest franchise and helps reinforce lenacapavir as a strategic asset, while the Trodelvy lung cancer setback limits one route for oncology upside. Gilead Sciences, Inc. shares were recently trading around $128.10, with a market capitalisation of about $160.6 billion, reflecting a company still viewed as financially strong but dependent on successful portfolio broadening beyond its core virology base.
For Merck & Co., Inc., the HIV result is positive but the oncology discontinuation lands in a more complicated strategic environment. Merck & Co., Inc. remains heavily exposed to Keytruda, with the Keytruda family generating $8.03 billion in first-quarter 2026 sales. The failure of a Keytruda plus Trodelvy lung cancer combination does not weaken Keytruda’s existing role, but it does remove one potential expansion route in a key tumour type. Merck & Co., Inc. shares were recently trading around $119.52, with a market capitalisation of about $295.2 billion, and investors remain focused on how the U.S.-based pharma major manages growth beyond Keytruda’s peak exclusivity window.
The investor takeaway is therefore asymmetrical. Gilead Sciences, Inc. gains more from the HIV readout than it loses from this particular Trodelvy study if lenacapavir-based regimens continue to deliver. Merck & Co., Inc. gains an important islatravir validation, but the company still needs broader late-stage pipeline execution to reduce dependence on Keytruda. Both companies can point to scientific progress, yet both still face the same industry reality: late-stage pharma value is increasingly created by clean datasets, not attractive mechanisms alone.
What will regulators, clinicians and industry observers watch after these two Phase 3 updates?
The next key step for the HIV programme is the release of detailed ISLEND-1 and ISLEND-2 data at a scientific meeting and subsequent regulatory submissions. Regulators will examine whether once-weekly islatravir and lenacapavir provides durable virologic control with a safety profile that can support broad switch use. Clinicians will focus on the practical details that topline releases cannot answer, including missed-dose management, resistance emergence, immune cell trends, tolerability, and whether the regimen works consistently across different baseline treatment histories.
For the lung cancer programme, attention will shift to the full KEYNOTE-D46/EVOKE-03 dataset and whether any lessons can be salvaged for future Trodelvy studies. The absence of new safety signals is reassuring, but it does not solve the efficacy problem. In first-line metastatic non-small cell lung cancer, a regimen must compete not only against Keytruda, but also against evolving chemoimmunotherapy, dual immunotherapy, and antibody-drug conjugate strategies from other developers.
The broader industry signal is that Gilead Sciences, Inc. and Merck & Co., Inc. remain active in two of the most competitive areas of biopharma: HIV and oncology. The HIV result could mark a genuine dosing-model shift if the final dataset is clean enough for regulators and practical enough for clinicians. The lung cancer discontinuation shows that even scientifically rational combinations can fail when the standard of care is strong and the incremental benefit is modest. That split makes the update more useful, not less, because it captures the real state of late-stage drug development in 2026: platform promise on one side, clinical discipline on the other.
Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →